All AbMole products are for research use only, cannot be used for human consumption.
GW788388 is a selective inhibitor of transforming growth factor-β type I receptor (ALK5) (IC50 values are 0.018 and 0.093 μM for ALK5 binding and for TGF-β cellular assay respectively). GW788388 inhibits esophageal squamous cell carcinoma (ESCC)-induced neoangiogenesis. GW788388 is orally available with a half-life of approximately 4 hours. GW788388 blocked TGF-beta-induced Smad activation and target gene expression, while decreasing epithelial-mesenchymal transitions and fibrogenesis. Treatment with GW788388 significantly reduced TGF-beta activity, leading to the attenuation of systolic dysfunction and left ventricular remodeling in an experimental rat model of MI.
| Molecular Weight | 425.48 |
| Formula | C25H23N5O2 |
| CAS Number | 452342-67-5 |
| Solubility (25°C) | DMSO 20 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related TGF-β Receptor Products |
|---|
| LY2157299
LY2157299 (Galunisertib) is a novel clinically relevant TBRI (ALK5 kinase) inhibitor with IC50 of 56 nM. |
| LY364947
LY364947 is a selective small molecule inhibitor of the TGFβ type I receptor kinase with IC50 of 59 nM. |
| LY2109761
LY2109761 is a novel TGF-β receptor type I and type II dual inhibitor, with Ki values of 38 nM and 300 nM, respectively. |
| SB-525334
SB-525334 is a potent activin receptor-like kinase (ALK5)/ type I TGFβ-receptor kinase inhibitor with IC50 of 14.3 nM. |
| SB-505124
Sb-505124 is a selective inhibitor of TGF-βI receptor (ALK4, ALK5, ALK7) with IC50 values of 129 nM and 47 nM for ALK4 and ALK5, respectively. Sb-505124 also inhibits ALK7, but not ALK1, 2, 3 and 6. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
